Globalization of Chinese Companies

  • Recommend
  • Tweet
  • Print
  • Email

Wednesday, October 24th, 8:30-9:55am

This panel will explore the globalization of Chinese companies, starting with the nuances of conducting business with Western biopharma companies and how to go about selling products outside of China. How can Chinese companies find local partners in new territories? What kinds of deal models are most prevalent in the West? Case studies showcasing strong, successful collaborations will provide strategic insight for Chinese companies eager to sell products beyond China’s borders.

Moderator:

  • Luo Xielong, President, Renhe Group & Executive Vice President, CPEA

Panelists:

  • Lily Han, PhD, Deputy General Manager of International Development, Fosun Pharma
  • May-Kin Ho, PhD, Advisory Director, Goldman, Sachs & Co.
  • Sammy Jiang, Associate President, Luye Pharma Group Ltd.

Who's Who

May-Kin Ho, PhD
Advisory Director, Goldman Sachs & Co.

Maykin is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. Maykin joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002.

Maykin has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times.

Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company.

Maykin serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School.

Maykin was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center.

Sammy Jiang
Associate President, Luye Pharma Group Ltd.

Ms. Sammy (Chinese name: Hua Jiang) is the associate president of Luye Pharma Group, in charge of group development strategy, products portfolio management and the group’s international collaboration, including business development, company alliance, and international trade. She is also the vice general manager Shandong International bioscience park (BIOasis), in charge of overseas promotion and projects introduction work.

Ms. Jiang holds a Master‘s degree in Business Administration from Euromed Marseille Ecole de Management School (2007) and a Bachelor’s degree in Economics from Economy School, Fudan University (1998). She is the economist certified by China’s National Bureau of Personnel.

Ms. Jiang is the honorary director of ACLSTA (American Chinese Life Science Technology Association). She was listed in “China’s Top 99 Pharma Executives” in 2010, and won “the national excellent award 2010,” given by SAPA (Sino America Pharmaceutical Association).

Ms. Jiang is a freelance writer for Healthcare Executive magazine, China Pharmaceutical Technology Economics and Management magazine and the Chamber of Commerce’s Import & Export of Medicines & Health Products monthly magazine. She is also a part time lecturer for Yantai University Pharmaceutical College, and has been named in the top 10% of professors in the pharmaceutical school of Yantai University, as elected by the students.

Luo Xielong
President, Renhe Group

Mr. Luo Xielong has been President of Renhe Group since 2010. He previously served as Deputy General Manager of Beijing Pharmaceutical Co., Ltd., Central Research Institute, President of Beijing Pharmaceutical Co., Ltd., and Chairman of Chinese Medicine Research and Development Center from 2003 to 2012; GM, Peking University Health Science Center Yikang Technology Corporation and GM, Scrianen Pharmaceutical from 1994 to 2002; Deputy General Manager, Hong Kong Yizhou Group and GM, Shenzhen Yizhou High-tech Industry Co., Ltd. from 1990 to 1993; Division Chief, Division of Medical Service, Health Department, Hangzhou and Deputy Director, Zhejiang Administration Committee of Hospitals from 1983 to 1990.

In addition, he is a consultant to the Chinese Medicine Department, UNIDO, Vice President, CABA, Vice President, CJMST, Executive Vice President, CPEA, Director, Professional Committee of China Pharmaceutical Enterprise Internationalization, Director, Preparatory Committee of China Pharmaceutical Enterprise Innovative Preparation Industry Alliance, Executive Vice Chairman, China Biopharm CRO Alliance, Executive Vice Director, Cosmeceuticals Committee, China OTC Association, President and Honorary President, Industry & Commerce Beautyculture & Cosmetics Chamber, President, Beijing Zhongguancun Enterprise Association Of Biotech.& Pharma, Consultant for Industry Plan and Investment of China Medical City Taizhou, Group Leader, Biopharm 12th Five-year Plan Development Plan Research Group, Zhejiang Development and Reform Committee, Management and Investment Consultant, Hangzhou Biological Industrial & National High-tech Industrial Zone. Besides above mentioned posts, Mr. Luo has also served as an independent director and management consultant for dozens of domestic and overseas companies.

Mr. Luo graduated from Harbin Medical University and holds an EMBA both from Sino-European International Management Institute (Project and Investment Management) and Peking University Experimental Testing Center for Economics and Management (Business Management).